Core Insights - Elicio Therapeutics announced new immunogenicity data from the Phase 2 AMPLIFY-7P trial for ELI-002 7P, showing strong T cell responses in patients with mKRAS pancreatic ductal adenocarcinoma [1][3][6] - The company also presented preclinical data for ELI-004, indicating over 90% tumor eradication in advanced solid tumors [1][8] Group 1: ELI-002 7P Immunogenicity Data - In the AMPLIFY-7P trial, 99% of 90 evaluable patients achieved robust mKRAS-specific T cell responses, with a mean increase of 145-fold over baseline [4][6] - 85% of patients exhibited combined CD4 and CD8 T cell activation, correlating with clinical activity [4][6] - 88% of patients generated responses to their own tumor-specific mutations, indicating personalized immune activation [4][6] Group 2: ELI-004 Preclinical Data - ELI-004 demonstrated complete tumor eradication in over 90% of cases in preclinical studies, with long-term protection against recurrence [3][8] - The efficacy of ELI-004 was linked to the presence of CD8 T cells and effective lymphocyte trafficking from lymph nodes [8] - This approach suggests a promising off-the-shelf strategy for solid tumor immunotherapy [8] Group 3: Presentation Details - The findings will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting [2] - The late-breaking abstract for ELI-002 7P highlights its potential to induce robust T cell immunity across diverse HLA backgrounds [6][7] Group 4: Company Overview - Elicio Therapeutics focuses on developing novel immunotherapies targeting high-prevalence cancers, particularly those driven by KRAS mutations [14] - The company's AMP platform aims to enhance immune responses by delivering therapeutics directly to lymph nodes [12][13] - Elicio plans to expand its pipeline to include additional indications for ELI-002 and other candidates targeting different mutations [14]